RESYNTHESIS COMPOUNDS Sample Clauses

RESYNTHESIS COMPOUNDS. In partial consideration of the delivery of [*****] resynthesis compounds (as described in Section 3.5.) per calendar quarter from the[*****] , Sankyo agrees to pay ArQule [*****] until the last payment is made on[*****]. If Sankyo does not receive its full allocation of [*****] compounds in a given calendar quarter, ----------------------- Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omissions. ArQule shall have no obligation to provide Sankyo with the shortfall in any subsequent calendar quarter. If Sankyo receives more than [*****] resynthesis compounds in a given calendar quarter, as requested by Sankyo, Sankyo agrees to pay ArQule [*****] thirty (30) days of receipt. In addition, if ArQule produces more than 5 mg of a resynthesis compound, as directed by the Research Committee and approved by Sankyo, Sankyo will pay ArQule an additional fee that will be determined by the Steering Committee on a case-by-case basis.
Sample 1
AutoNDA by SimpleDocs
RESYNTHESIS COMPOUNDS. In partial consideration of the delivery of up to fifteen (15) resynthesis compounds (as described in Section 3.5.) per calendar quarter from the Effective Date through March 31, 2003, Sankyo agrees to pay ArQule a delivery fee in the amount of $300,000 in eight (8) equal installments of $37,500, payable within two (2) weeks after the Effective Date and thereafter on the first day of each calendar quarter until the last payment is made on January 1, 2003. If Sankyo does not receive its full allocation of fifteen (15) resynthesis compounds in a given calendar quarter, ArQule shall have no obligation to provide Sankyo with the shortfall in any subsequent calendar quarter. If Sankyo receives more than fifteen (15) resynthesis compounds in a given calendar quarter, as requested by Sankyo, Sankyo agrees to pay ArQule $2,500 for each such additional resynthesis compound within thirty (30) days of receipt. In addition, if ArQule produces more than 5 mg of a resynthesis compound, as directed by the Research Committee and approved by Sankyo, Sankyo will pay ArQule an additional fee that will be determined by the Steering Committee on a case-by-case basis.
Sample 1

Related to RESYNTHESIS COMPOUNDS

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Commercialization Diligence Upon receipt of the Marketing Authorization for a Licensed Product in the Field in a given Region in the Territory, Lian (directly, or through its Affiliates, Sublicensees or contractors) will use Commercially Reasonable Efforts to Commercialize such Licensed Product in the Field in such Region in the Territory. Lian will have sole decision-making authority and discretion with respect to Commercializing the Licensed Product in the Field in the Territory. [***].

  • Product Testing Upon request, Customer shall provide Operator a laboratory report for each Product delivery by Customer or Customer’s supplier. Operator will not be obligated to receive Contaminated Product for throughput through the Pipelines, nor will Operator be obligated to accept Product that fails to meet the applicable quality specifications for the Berths under the BAUTA and any Terminal Service Orders issued thereunder.

  • Product The term “

  • API A. Reliant shall supply to Cardinal Health for Manufacturing and Packaging, at Reliant’s sole cost, the API and applicable reference standards in quantities sufficient to meet Reliant’s requirements for each Product as further set forth in Article 4. Prior to delivery of any of the API or reference standard to Cardinal Health for Manufacturing and Packaging, Reliant shall provide to Cardinal Health a copy of the API Material Safety Data Sheet (“MSDS”), as amended, and any subsequent revisions thereto. Reliant shall supply the API, reference standards, and Certificate of Analysis FOB the Facility no later than thirty (30) days before the scheduled Manufacture Date upon which such API will be used by Cardinal Health. Upon receipt of the API, Cardinal Health shall conduct identification testing of the API. Cardinal Health shall use the API solely and exclusively for Manufacturing and Packaging under this Agreement. The maximum volume of API that Reliant supplies to Cardinal Health shall not exceed the amount reflected in the Firm Commitment and the next six (6) months of the Rolling Forecast.

  • Manufacture (a) Manufacturer shall only manufacture the specific number of Products as requested by Company and at no time shall manufacture excess goods or overruns. Manufacturer shall not sell any Products bearing the Trademarks to any third parties without the express written consent of Company.

  • Research Collaboration (a) GSK hereby grants to Anacor a non-exclusive, non-royalty bearing license under the GSK IP, solely as and to the extent necessary or important to conduct activities for which Anacor is responsible under the Research Plans during the Research Collaboration Term.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

Time is Money Join Law Insider Premium to draft better contracts faster.